LIN XU: Open Payments
NPI 1184675712 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$380 in 15 payments from 9 companies in 2025. Trend: 2023 $1,928 · 2024 $1,371 · 2025 $380
Food & beverage: $380
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 1 | $99 |
| ABBVIE INC. | 5 | $93 |
| Alkermes, Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Noven Therapeutics, LLC | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
Products named: AUSTEDO XR, VRAYLAR, ARISTADA, TRINTELLIX, Secuado, REXULTI, FANAPT, CAPLYTA.
Industry payments across KS — which companies pay providers there.
